Hoy Sheridan M
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Paediatr Drugs. 2025 May;27(3):383-391. doi: 10.1007/s40272-025-00689-3.
The aryl hydrocarbon receptor (AhR) has an integral role in maintaining skin homeostasis. Tapinarof cream 1% (VTAMA) is an AhR agonist developed by Dermavant Sciences, an Organon Company, as a once-daily topical treatment for plaque psoriasis and atopic dermatitis (AD). It was first approved in May 2022 in the USA for the topical treatment of plaque psoriasis in adults. It was then approved in June 2024 in Japan for the topical treatment of plaque psoriasis in adults and AD in adults and pediatric patients 12 years of age and older. In December 2024, it was approved in the USA for the topical treatment of AD in adults and pediatric patients 2 years of age and older. This article summarizes the milestones in the development of tapinarof cream 1% leading to this first pediatric approval.
芳烃受体（AhR）在维持皮肤稳态中起着不可或缺的作用。1%他扎罗汀乳膏（VTAMA）是由欧加农公司旗下的德马万特科学公司研发的一种AhR激动剂，用于治疗斑块状银屑病和特应性皮炎（AD），每日一次局部用药。它于2022年5月在美国首次获批用于成人斑块状银屑病的局部治疗。随后于2024年6月在日本获批用于成人斑块状银屑病以及成人和12岁及以上儿童患者的AD的局部治疗。2024年12月，它在美国获批用于成人和2岁及以上儿童患者AD的局部治疗。本文总结了1%他扎罗汀乳膏研发过程中促成此次首次儿科批准的各个重要节点。
